logo-loader
viewScancell Holdings PLC

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

immune
Scancell makes selective immunotherapy agents that help the body overcome the immune suppression induced by tumours

Scancell Holdings PLC (LON:SCLP), the cancer immunotherapy specialist, has raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company when the shares are issued next Monday.

WATCH: Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

Along with the stake in the company, Martin Diggle, co-founder of the fund’s owner, Vulpes Investment Management, and an experienced investor in the life science sector, has been proposed as a non-executive director.

Diggle, having conducted scientific and commercial due diligence on Scancell for some time, said Vulpes felt it was an “exciting time” in the evolution of the company, where he believed its “unique and innovative approach to fighting cancer is compelling and under-appreciated”.

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Scancell chairman John Chiplin said: “This new investment capital increases funds available to advance our product pipeline and in particular, the transition of our lead Moditope platform asset Modi-1 into the clinic.

Modi-1, part of a new class of selective immunotherapy agents that stimulate the production of killer T cells that overcome the immune suppression induced by tumours, is expected to enter the clinic in the first quarter of 2020 in multiple tumour types, including head and neck, breast and ovarian cancer.

Scancell shares were up almost 8% to 5.76p in early trading on Thursday.

Quick facts: Scancell Holdings PLC

Price: 5.05 GBX

LSE:SCLP
Market: LSE
Market Cap: £23.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibody collaboration deal for Scancell

Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly. CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing...

on 5/9/19

2 min read